Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders
Ida Emilia Aasen1, Geir Øgrim2, Juri Kropotov3
1Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neuropsychology, Helgeland Hospital, Mosjøen, Norway.
Abstract:
Methylphenidate (MPH) has been shown to modulate the amplitude of the no-go P3 component of the event-related potential (ERP; Øgrim, Aasen, & Brunner, 2016). Using group independent component analysis, the no-go P3 from a cued go/no-go task has been separated into two sub-components (Brunner et al., 2013). This study investigated whether sub-components of the no-go P3 could be identified in children with ADHD, and how MPH modulates their amplitudes. ERPs were registered twice (on/off MPH) in 57 children with ADHD classified as medication responders in a four-week medication trial. Two no-go P3 sub-components were identified. In the MPH session, the amplitude of one sub-component, the IC P3no-goearly (mean latency 378 ms, with a central distribution), was significantly larger than at baseline, whereas the other sub-component, the IC P3no-golate (mean latency 428 ms, with a centro-frontal distribution), was not significantly affected. These results add to the literature documenting that the no-go P3 consists of two overlapping phenomena with different functional correlates.
Insights
Methylphenidate (MPH) treatment increased the amplitude of an early sub-component of the no-go P3 event-related potential (ERP) in children with ADHD. A later sub-component remained unaffected, suggesting distinct functional roles.
Area of Science:
- Neuroscience
- Psychopharmacology
- Cognitive Electrophysiology
Background:
- Methylphenidate (MPH) is known to modulate the no-go P3 event-related potential (ERP) amplitude.
- The no-go P3 can be decomposed into distinct sub-components using independent component analysis (ICA).
- Understanding these sub-components is crucial for elucidating the neural mechanisms underlying ADHD and MPH effects.
Purpose of the Study:
- To identify and characterize sub-components of the no-go P3 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).
- To investigate the modulatory effects of Methylphenidate (MPH) on the amplitudes of these identified no-go P3 sub-components.
- To explore the functional correlates of distinct no-go P3 sub-components in the context of ADHD treatment.
Main Methods:
- Electroencephalography (EEG) recordings were obtained from 57 children with ADHD twice: once on Methylphenidate (MPH) and once at baseline.
- Participants were classified as medication responders following a four-week MPH trial.
- Group independent component analysis (gICA) was employed to separate the no-go P3 into sub-components from a cued go/no-go task.
Main Results:
- Two distinct no-go P3 sub-components were successfully identified in children with ADHD.
- The amplitude of the early sub-component (IC P3no-goearly, mean latency 378 ms, central distribution) significantly increased during MPH treatment compared to baseline.
- The late sub-component (IC P3no-golate, mean latency 428 ms, centro-frontal distribution) showed no significant modulation by MPH.
Conclusions:
- The findings support the notion that the no-go P3 comprises at least two overlapping neural processes with differing functional roles.
- Methylphenidate (MPH) selectively enhances the amplitude of an early, centrally distributed no-go P3 sub-component in children with ADHD.
- These results contribute to a more nuanced understanding of the neurophysiological effects of MPH in ADHD, highlighting differential modulation of distinct ERP components.
Related Concept Videos
Inhaled Medications
Components of Language
Components of Stress
Interestingly, the hidden cube faces also experience these stresses, equal and...
What is Natural Selection?
Pharmacokinetics in Pediatric Patients: Drug Excretion
Antibiotic Selection


